IVZ Stock Analysis: | NYSE

Asset Management | NYSE, USA | Market Cap: 11.902m USD | 12M Return: 25.4% | BMG491BT1088 | Charts, Fundamentals & Technical Analysis

Mutual Funds, Exchange-Traded Funds, Equity Portfolios, Fixed Income
Total Rating 45
Safety 67
Buy Signal 0.06
Asset Management & Custody Banks
Sub-Industry Rotation: +0.7
Market Cap: 11.9B
Avg Turnover: 159M
Risk 3d forecast
Volatility36.3%
VaR 5th Pctl6.23%
VaR vs Median4.27%
Reward TTM
Sharpe Ratio0.70
Rel. Str. IBD56.5
Rel. Str. Peer Group64.4 pctl
Character TTM
Beta1.864
Beta Downside1.787
Hurst Exponent0.395
Choppyness51.4%
Drawdowns 3y
Max DD36.52%
CAGR/Max DD0.92
CAGR/Mean DD3.88
EPS (Earnings per Share) EPS (Earnings per Share) of IVZ over the last years for every Quarter: "2021-09": 0.77, "2021-12": 0.86, "2022-03": 0.56, "2022-06": 0.39, "2022-09": 0.34, "2022-12": 0.39, "2023-03": 0.38, "2023-06": 0.31, "2023-09": 0.35, "2023-12": 0.47, "2024-03": 0.33, "2024-06": 0.43, "2024-09": 0.44, "2024-12": 0.52, "2025-03": 0.44, "2025-06": 0.36, "2025-09": 0.61, "2025-12": 0.62, "2026-03": 0.57, "2026-06": 0.71, "2026-09": 0.72,
EPS CAGR: 22.33%
EPS Trend: 96.7%
Last SUE: -0.48
Qual. Beats: 0
Revenue Revenue of IVZ over the last years for every Quarter: 2021-09: 1750, 2021-12: 1763.4, 2022-03: 1629.4, 2022-06: 1530.4, 2022-09: 1445.7, 2022-12: 1443.4, 2023-03: 1418.2, 2023-06: 1442.8, 2023-09: 1442, 2023-12: 1413.4, 2024-03: 1475.3, 2024-06: 1483.3, 2024-09: 1515.4, 2024-12: 1593, 2025-03: 1529.2, 2025-06: 1515.5, 2025-09: 1640.4, 2025-12: 1692, 2026-03: 1744.5, 2026-06: 1825.6, 2026-09: 1873.2,
Rev. CAGR: 7.90%
Rev. Trend: 96.8%
Last SUE: 0.84
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.9 years of data, until 10/2026

Jan +0.3% 0
Feb -2.1% 14
Mar +0.1% 0
Apr +0.3% 4
May +0.3% 4
Jun -1.6% 0
Jul +5.5% 14
Aug -3.1% 14
Sep -0.3% 4
Oct +1.3% 0
Nov +6.1% 21
Dec -0.7% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: IVZ

Invesco Ltd. (IVZ) is a publicly owned, large-cap global investment manager founded in 1935 and headquartered in Atlanta, Georgia, with additional offices across Asia, Europe, Africa, and North America. The firm serves a broad client base that includes retail, institutional, high-net-worth, public, corporate, and nonprofit entities, as well as pension funds, financial institutions, and sovereign wealth funds. Operating within the GICS Financials sector (Asset Management & Custody Banks sub-industry), Invesco offers equity, fixed income, commodity, multi-asset, and balanced products through mutual funds, exchange-traded funds (ETFs), and private funds.

The firm invests across global public equity and fixed income markets, as well as alternative markets such as commodities and currencies, with a stated preference for equity investments of $5 million to $15 million per company. Its equity strategies span growth and value styles across large-, mid-, and small-cap segments, while its fixed income approach covers government, municipal, and Treasury securities, convertibles, investment-grade and high-yield bonds, senior secured loans, and structured products including asset-backed, mortgage-backed, and commercial mortgage-backed securities. Invesco employs absolute return, global macro, long/short, and quantitative strategies, and trades on the NYSE under the ticker IVZ, having gone public in August 1995.

Headlines to Watch Out For
  • QQQ ETF assets hit record on sustained tech inflows
  • Active equity outflows pressure fee-based margins
  • Capital return continues via dividend and buyback program
Piotroski VR-10 (Strict) 4.5
Net Income: -78.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.60 > 1.0
NWC/Revenue: -12.98% < 20% (prev 18.80%; Δ -31.78% < -1%)
CFO/TA 0.07 > 3% & CFO 1.84b > Net Income -78.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.65 > 1.5 & < 3
Outstanding Shares: last quarter (452.5m) vs 12m ago -0.46% < -2%
Gross Margin: 74.60% > 18% (prev 35.41%; Δ 39.19% > 0.5%)
Asset Turnover: 25.44% > 50% (prev 22.08%; Δ 3.37% > 0%)
Interest Coverage Ratio: -3.12 > 6 (EBIT TTM -284.5m / Interest Expense TTM 91.2m)
Altman Z'' 1.42
A: -0.03 (Total Current Assets 1.75b - Total Current Liabilities 2.68b) / Total Assets 27.6b
B: 0.23 (Retained Earnings 6.47b / Total Assets 27.6b)
C: -0.01 (EBIT TTM -284.5m / Avg Total Assets 28.0b)
D: 0.90 (Book Value of Equity 12.6b / Total Liabilities 14.0b)
Altman-Z'' = 1.42 = BB
Beneish M -3.72
DSRI: 0.60 (Receivables 787.6m/1.15b, Revenue 7.14b/6.28b)
GMI: 0.47 (GM 35.41% / 74.60%)
AQI: 1.03 (AQ_t 0.92 / AQ_t-1 0.89)
SGI: 1.14 (Revenue 7.14b / 6.28b)
TATA: -0.07 (NI -78.7m - CFO 1.84b) / TA 27.6b)
Beneish M = -3.72 (Cap -4..+1) = AAA
What is the price of IVZ shares?

As of November 16, 2026, the stock is trading at USD 28.92 with a total of 6,108,388 shares traded. Over the past week, the price has changed by +7.61%, over one month by +0.76%, over three months by -9.35% and over the past year by +25.38%.

Current recommended Stop Loss: 27.20 (which is 5.9% or 1.6 ATR below the current price).

Is IVZ a buy, sell or hold?

has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold IVZ.

  • StrongBuy: 4
  • Buy: 2
  • Hold: 9
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the IVZ price?
Analysts Target Price 35.1 21.3%
(IVZ) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 11.9b (11.9b USD * 1.0 USD.USD)
P/E Forward = 9.1408
P/S = 1.6681
P/B = 1.2787
P/EG = 0.9008
Revenue TTM = 7.14b USD
EBIT TTM = -284.5m USD
EBITDA TTM = -175.1m USD
Long Term Debt = 9.20b USD (from longTermDebt, last quarter)
Short Term Debt = 66.6m USD (from shortTermDebt, last fiscal year)
Debt = 9.67b USD (corrected: LT Debt 9.20b + ST Debt 66.6m) + Leases 406.7m
Net Debt = 8.71b USD (calculated: Debt 9.67b - CCE 965.5m)
Enterprise Value = 20.6b USD (11.9b + Debt 9.67b - CCE 965.5m)
Interest Coverage Ratio = -3.12 (Ebit TTM -284.5m / Interest Expense TTM 91.2m)
EV/FCF = 11.60x (Enterprise Value 20.6b / FCF TTM 1.78b)
FCF Yield = 8.62% (FCF TTM 1.78b / Enterprise Value 20.6b)
FCF Margin = 24.91% (FCF TTM 1.78b / Revenue TTM 7.14b)
Net Margin = -1.10% (Net Income TTM -78.7m / Revenue TTM 7.14b)
Gross Margin = 74.60% ((Revenue TTM 7.14b - Cost of Revenue TTM 1.81b) / Revenue TTM)
Gross Margin QoQ = 65.64% (prev none%)
Tobins Q-Ratio = 0.75 (Enterprise Value 20.6b / Total Assets 27.6b)
Interest Expense / Debt = 0.94% (Interest Expense 91.2m / Debt 9.67b)
Taxrate = 23.35% (108.3m / 463.9m)
NOPAT = -218.1m (EBIT -284.5m * (1 - 23.35%)) [loss with tax shield]
Current Ratio = 0.65 (Total Current Assets 1.75b / Total Current Liabilities 2.68b)
Debt / Equity = 0.77 (Debt 9.67b / totalStockholderEquity, last quarter 12.6b)
 Debt / EBITDA = -49.74 (negative EBITDA) (Net Debt 8.71b / EBITDA -175.1m)
 Debt / FCF = 4.90 (Net Debt 8.71b / FCF TTM 1.78b)
Total Stockholder Equity = 12.4b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.28% (Net Income -78.7m / Total Assets 27.6b)
RoE = -0.63% (Net Income TTM -78.7m / Total Stockholder Equity 12.4b)
RoCE = -1.32% (EBIT -284.5m / Capital Employed (Equity 12.4b + L.T.Debt 9.20b))
 RoIC = -0.88% (negative operating profit) (NOPAT -218.1m / Invested Capital 24.7b)
 WACC = 6.88% (E(11.9b)/V(21.6b) * Re(11.89%) + D(9.67b)/V(21.6b) * Rd(0.94%) * (1-Tc(0.23)))
Discount Rate = 11.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -77.13 | Cagr: -0.35%
[DCF] Terminal Value 77.97% ; FCFF base≈1.62b ; Y1≈1.85b ; Y5≈2.73b
[DCF] Fair Price = 73.51 (EV 41.0b - Net Debt 8.71b = Equity 32.3b / Shares 439.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.71 | EPS CAGR: 22.33% | SUE: -0.48 | # QB: 0
Revenue Correlation: 96.84 | Revenue CAGR: 7.90% | SUE: 0.84 | # QB: 1
EPS current Quarter (2027-03-31): EPS=0.71 | Chg30d=+0.01% | Revisions=+12% | Analysts=10
EPS current Year (2026-12-31): EPS=2.78 | Chg30d=-0.95% | Revisions=-50% | GrowthEPS=+37.1% | GrowthRev=+15.2%
EPS next Year (2027-12-31): EPS=3.30 | Chg30d=+0.81% | Revisions=-42% | GrowthEPS=+18.5% | GrowthRev=+7.3%
[Analyst] Revisions Ratio: -39% (up=7, down=18)